Citrobacter freundii is one species within the Citrobacter genus. It can occur in the intestinal microbiota and can cause opportunistic infections in other settings. A stool DNA quantity does not establish which role it is playing in an individual person.
On this page
Why a species result adds detail but not a diagnosis
A species-targeted result is narrower than Citrobacter spp., but it still does not provide the strain’s complete genetic profile. Research has isolated C. freundii and related Enterobacterales from healthy subjects, illustrating why detection alone is not equivalent to disease. [1]
Reading the GI-MAP value
GI-MAP reports C. freundii separately from the genus target. A high value is a comparison with the laboratory’s range. It is not a direct measure of tissue invasion, toxin activity or the severity of digestive symptoms. [2]
What the result cannot establish
It cannot identify a urinary or bloodstream infection, select an antibiotic or show that Citrobacter caused an autoimmune condition. The report’s category is not a clinical diagnosis.
If you have a separate culture showing C. freundii, review the specimen source, date and susceptibility information with the clinician. A DNA quantity from stool cannot replace that culture or prove that a previously treated infection has cleared.
When to investigate beyond the report
Persistent diarrhea, unexplained weight loss or significant pain needs clinical assessment rather than a species-by-species eradication plan. If you are immunocompromised and have fever or feel acutely unwell, contact your care team promptly. The stool number cannot assess systemic illness.
Common questions
Is a high C. freundii result proof of a resistant infection?
No. Resistance and active infection require additional, relevant evidence.
Should the genus and species counts match?
Not necessarily. Different targets and reporting methods can produce different values. Ask the laboratory about unexpected patterns rather than adding the figures together.
Sources and review
Sources checked October 7, 2026. Manufacturer material describes the test; clinical guidance and research support the interpretation limits.
- Enterobacterales isolated from healthy subjects: primary study, 2020
- Diagnostic Solutions Laboratory: GI-MAP interpretive guide (manufacturer specifications)
Medical review of this article is pending. For a correction or source question, contact GI MAP Test.